Mitsubishi Tanabe Plans Five Phase III China Drug Trials In Five Years
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharma plans five Phase III trials of its drugs in China over the next five years, using earlier data from trials.